Aurobindo Pharma’s arm gets nod to expand mammalian cell culture manufacturing facility

02 Sep 2022 Evaluate

Aurobindo Pharma’s wholly owned subsidiary -- CuraTeO Biologics (CuraTeQ) has received approval to expand its operations by establishing another mammalian cell culture manufacturing facility of higher capacity to cater to the future requirements. The capital expenditure for ramping up capacities is estimated to be around Rs 300 crore. Subject to regulatory approvals and other factors, the facility is likely to be fully operational by FY 2026.

CuraTeQ also received approval to enter into contract manufacturing operations (ICCMO) for biologicals for effective utilization of capacities and augmenting the business prospects in this area as the global biologics contract manufacturing demand is growing at 8 to 10% rate. CuraTeQ will actively seek customers in CMO area.

Also, Aurobindo Pharma’s wholly owned subsidiary -- Auro Vaccines (Auro), which is engaged in business of developing and manufacturing vaccines biologicals has decided to explore the possibilities of offering contract manufacturing to global vaccine developers so as to effectively utilise its existing manufacturing capacity. Aurobindo Pharma will actively seek customers in this space.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1172.30 -7.95 (-0.67%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×